Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Essential Thrombocythemia Market to Witness Upsurge in Growth During the Study Period (2020–2034) | DelveInsight

New York, USA, March 05, 2025 (GLOBE NEWSWIRE) -- Essential Thrombocythemia Market to Witness Upsurge in Growth During the Study Period (2020–2034) | DelveInsight The essential thrombocythemia...
May 03, 2022 08:00 ET | Source: Imago Biosciences, Inc.

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
December 01, 2021 08:00 ET | Source: Imago Biosciences, Inc.

Imago BioSciences to Host Virtual Investor Event

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
November 11, 2021 16:05 ET | Source: Imago Biosciences, Inc.

Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
November 10, 2021 16:05 ET | Source: Imago Biosciences, Inc.

Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
August 05, 2020 07:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update

Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...